Literature DB >> 16554399

Measuring health-related quality of life in patients with irritable bowel syndrome: can less be more?

Jeffrey M Lackner1, Gregory D Gudleski, Matthew M Zack, Leonard A Katz, Catherine Powell, Susan Krasner, Elizabeth Holmes, Kathryn Dorscheimer.   

Abstract

OBJECTIVE: This study assessed the ability of a brief, well-validated generic health-related quality of life (HRQOL) measure to characterize the symptom burden of patients with irritable bowel syndrome (IBS) with reference to a large survey of U.S. community-living adults.
METHODS: One hundred four Rome II diagnosed patients with IBS completed measures of pain, psychological dysfunction (neuroticism, somatization, distress, abuse), and HRQOL (SF-36, IBS-QOL, CDC HRQOL-4) during baseline assessment of a National Institutes of Health-funded clinical trial. The four-item CDC HRQOL-4 assesses global health and the number of days in the past 30 days resulting from poor physical health, poor mental health, and activity limitation.
RESULTS: Patients with IBS averaged 15 of 30 days with poor physical or mental health. These average overall unhealthy days exceeded those of respondents with arthritis, diabetes, heart disease/stroke, cancer, and class III obesity (body mass index > or =40 kg/m2) from the U.S. survey. Fifteen percent of patients identified musculoskeletal disorders, not IBS symptoms, as the major cause of their activity limitation. Overall unhealthy days among patients with IBS varied directly with IBS symptom severity, abuse, pain, and psychological distress. Controlling for personality variables that influence perception and reporting HRQOL did not diminish the statistical significance of associations between the CDC HRQOL-4 and other study measures.
CONCLUSIONS: The CDC HRQOL-4 is a psychometrically sound, rapid, and efficient instrument whose HRQOL profile reflects the symptom burden of moderate-to-severe IBS, is sensitive to treatment effects associated with cognitive behavior therapy, and is not a proxy for personality variables identified as potential confounders of HRQOL. HRQOL is related to but not redundant with psychological distress.

Entities:  

Mesh:

Year:  2006        PMID: 16554399     DOI: 10.1097/01.psy.0000204897.25745.7c

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  25 in total

1.  Time trends in gastroparesis treatment.

Authors:  Anwar Dudekula; Shiraz Rahim; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2014-09-26       Impact factor: 3.199

2.  Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.

Authors:  B M R Spiegel; R Bolus; L A Harris; S Lucak; W D Chey; G Sayuk; E Esrailian; A Lembo; H Karsan; K Tillisch; J Talley; L Chang
Journal:  Aliment Pharmacol Ther       Date:  2010-08-30       Impact factor: 8.171

3.  The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Laurie Keefer; James Jaccard; Rebecca Firth; Darren Brenner; Jason Bratten; Laura J Dunlap; Changxing Ma; Mark Byroads
Journal:  Contemp Clin Trials       Date:  2012-07-28       Impact factor: 2.226

4.  Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Chang-Xing Ma; Laurie Keefer; Darren M Brenner; Gregory D Gudleski; Nikhil Satchidanand; Rebecca Firth; Michael D Sitrin; Leonard Katz; Susan S Krasner; Sarah K Ballou; Bruce D Naliboff; Emeran A Mayer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-03-21       Impact factor: 11.382

5.  Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort.

Authors:  Brennan Spiegel; Lucinda Harris; Susan Lucak; Emeran Mayer; Bruce Naliboff; Roger Bolus; Eric Esrailian; William D Chey; Anthony Lembo; Hetal Karsan; Kirsten Tillisch; Gareth Dulai; Jennifer Talley; Lin Chang
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

6.  Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores.

Authors:  Jeffrey M Lackner; James Jaccard; Charles Baum
Journal:  Value Health       Date:  2012-11-30       Impact factor: 5.725

7.  Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale.

Authors:  B Spiegel; R Bolus; L A Harris; S Lucak; B Naliboff; E Esrailian; W D Chey; A Lembo; H Karsan; K Tillisch; J Talley; E Mayer; L Chang
Journal:  Aliment Pharmacol Ther       Date:  2009-09-12       Impact factor: 8.171

8.  Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility.

Authors:  Jeffrey M Lackner; James Jaccard; Susan S Krasner; Leonard A Katz; Gregory D Gudleski; Kenneth Holroyd
Journal:  Clin Gastroenterol Hepatol       Date:  2008-06-04       Impact factor: 11.382

9.  Negative aspects of close relationships are more strongly associated than supportive personal relationships with illness burden of irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Gregory D Gudleski; Rebecca Firth; Laurie Keefer; Darren M Brenner; Katie Guy; Camille Simonetti; Christopher Radziwon; Sarah Quinton; Susan S Krasner; Leonard Katz; Guido Garbarino; Gary D Iacobucci; Michael D Sitrin
Journal:  J Psychosom Res       Date:  2013-04-30       Impact factor: 3.006

10.  How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial.

Authors:  Jeffrey M Lackner; James Jaccard; Susan S Krasner; Leonard A Katz; Gregory D Gudleski; Edward B Blanchard
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.